X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Russia roll out the homegrown Sputnik V vaccine for its population

Content Team by Content Team
9th December 2020
in Drug Development, News
Russia roll out the homegrown Sputnik V vaccine for its population

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

In a first, Russia has started to roll out the homegrown Sputnik V vaccine for its population. This development comes just before the UK’s rollout of Pfizer vaccine, which is slated for this week. Sputnik V has been made available in Moscow starting Saturday. Initially, it shall be administered to doctors, teachers and social workers. Russia is the fourth worst-hit country from this deadly virus and there is no respite from it as the numbers continue to rise. The Russian officials are planning for a nationwide vaccination campaign starting next week. That said, it will be a limited scale roll out as the manufacturers have encountered challenges in ramping up production.

There has been a significant decrease in the estimated number of doses from the previously thought of strategy. Russia is now expecting to produce between 2 million and 10 million doses by this year-end as against the erstwhile 30 million doses which were planned during the vaccine’s launch in August. Russia was the first country to approve COVID-19 vaccine amidst the apprehension raised by many upon the speed with which it was developed. The country even faced criticism for not having large scale clinical trial data to support the vaccine’s efficacy.

Moscow has opened doors to 70 vaccination centres in Hospitals and Clinics from Saturday morning. People have started receiving text messages on their eligibility of getting vaccinated and have therefore enrolled online to get the shot. Looks like Kremlin is leaving no loose ends to make Sputnik V a success as it has not introduced any second lockdown despite the growing number of COVID cases.

It needs to be added that the jab is free of cost for the Russian citizens.  In Moscow alone, from a population of 12 million, around 5000 signed up for the first shot on Friday. The entire procedure for vaccination would take around an hour wherein there would be a pre and post-shot doctor examination as well as an observation window of 30 minutes. Those vaccinated will then receive a text message after three weeks for their next shot.  With all that there is, vaccine scepticism is still pounding. Officials have said that around 70% of the population needs to be vaccinated to halt the spread, but as per a recent poll conducted by Levada centre, only 36% would get injected.

Although there has been a decline in the expected dosage manufacturing numbers, President Putin says that he sees this as an opportunity to start if not mass, a large scale vaccination. Russia has 11 time zones and all are gearing up for a vaccine roll out next week. Authorities in St. Petersburg have started buying freezers that can maintain ultra-low temperatures, which is a primary requirement to store the jab.

Previous Post

From “Approved” to “Available” – Innovations in Scaling Parenteral Drug Manufacturing

Next Post

The UK begins the biggest ever immunization program

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
Next Post
The UK begins the biggest ever immunization program

The UK begins the biggest ever immunization program

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In